{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T02:30:38Z","timestamp":1786415438050,"version":"build-2736575974"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"DOI":"10.1007\/s00210-026-05793-w","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T02:06:08Z","timestamp":1786413968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world safety of aflibercept 8\u00a0mg in neovascular age-related macular degeneration"],"prefix":"10.1007","author":[{"given":"Wan-Ju Annabelle","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Hsiang-Te","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward Chia-Cheng","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"issue":"1","key":"5793_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-024-03788-w","volume":"24","author":"L Hoffmann","year":"2024","unstructured":"Hoffmann L, Michels S, Eandi C, Karam MA, Figueiredo ECO, Hatz K (2024) Aflibercept high-dose (8mg) related intraocular inflammation (IOI) - a case series. BMC Ophthalmol 24(1):520. https:\/\/doi.org\/10.1186\/s12886-024-03788-w","journal-title":"BMC Ophthalmol"},{"issue":"1","key":"5793_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ophtha.2025.08.022","volume":"133","author":"P Investigators","year":"2026","unstructured":"Investigators P, Korobelnik J-F, Lanzetta P et al (2026) Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial. Ophthalmology 133(1):39\u201350. https:\/\/doi.org\/10.1016\/j.ophtha.2025.08.022","journal-title":"Ophthalmology"},{"issue":"6","key":"5793_CR3","doi-asserted-by":"publisher","first-page":"9267","DOI":"10.1007\/s00210-025-04931-0","volume":"399","author":"WJA Lee","year":"2026","unstructured":"Lee WA, Tsai DH, Shao SC, Lai EC (2026) Intraocular inflammation incidence and real-world safety of intravitreal faricimab treatment across retinal indications. Naunyn Schmiedebergs Arch Pharmacol 399(6):9267\u20139273. https:\/\/doi.org\/10.1007\/s00210-025-04931-0","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"5793_CR4","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-026-04459-4","author":"WJA Lee","year":"2026","unstructured":"Lee WA, Tsai DH, Cheng MC et al (2026) Comparison of adverse renal events between ranibizumab and aflibercept in patients with diabetic macular oedema: a global network study. Eye (Lond). https:\/\/doi.org\/10.1038\/s41433-026-04459-4","journal-title":"Eye (Lond)"},{"issue":"3","key":"5793_CR5","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.oret.2023.12.001","volume":"8","author":"B Momenaei","year":"2024","unstructured":"Momenaei B, Wang K, Kazan AS et al (2024) Rates of ocular adverse events after intravitreal faricimab injections. Ophthalmol Retina 8(3):311\u2013313. https:\/\/doi.org\/10.1016\/j.oret.2023.12.001","journal-title":"Ophthalmol Retina"},{"issue":"5","key":"5793_CR6","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1097\/iae.0000000000004394","volume":"45","author":"A Montesel","year":"2025","unstructured":"Montesel A, Sen S, Preston E et al (2025) Intraocular inflammation associated with faricimab therapy: one-year real-world outcomes. Retina 45(5):827\u2013832. https:\/\/doi.org\/10.1097\/iae.0000000000004394","journal-title":"Retina"},{"issue":"1","key":"5793_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40942-025-00768-0","volume":"12","author":"LN Stoehr","year":"2025","unstructured":"Stoehr LN, Wakili P, Darwisch W et al (2025) Intraocular inflammation following aflibercept 8 mg: real-world data from a multicentre retrospective observational study. Int J Retina Vitreous 12(1):6. https:\/\/doi.org\/10.1186\/s40942-025-00768-0","journal-title":"Int J Retina Vitreous"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05793-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05793-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05793-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T02:06:09Z","timestamp":1786413969000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05793-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":7,"alternative-id":["5793"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05793-w","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. This study involved a secondary analysis of existing de-identified data and did not involve any intervention or interaction with human participants. The data were de-identified in accordance with the standard defined in Section \u00a7164.514(a) of the HIPAA Privacy Rule. The process by which the data is de-identified is attested to through a formal determination by a qualified expert as defined in Section \u00a7164.514(b)(1) of the HIPAA Privacy Rule. This formal determination by a qualified expert was refreshed in December 2020.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}